| Dr. Friedland is the Director of the AIDS Program at Yale New Haven Hospital and Yale
School of Medicine and Professor of Medicine and Epidemiology and Public Health. Dr. Friedland has been directly
involved in the provision of care to people living with HIV and the development of comprehensive care programs
since the beginning of the HIV epidemic. His work was initially in the Bronx, New York and since 1991, in New Haven,
Connecticut. He has developed and large scale epidemiologic studies among populations with and at risk for HIV disease.
His research initially focused on the routes of transmission of HIV disease, particularly among injection drug users.
His group presented the first convincing evidence of lack of transmission of HIV by close personal contact and defined
the predictors of HIV transmission and natural history of HIV disease among injection drug users.
|
|
More recently, Dr. Friedland has worked in the area of tuberculosis and in clinical trials
of antiretroviral therapies. In this work, as well, he has focused on the recruitment, enrollment, retention and special
issues of HIV therapeutics among injection drug users and other marginalized populations. These include access and
adherence to therapies, drug interactions between HIV and substance abuse therapies and interventions to reduce HIV
transmission risk among HIV+ persons in clinical care. Dr. Friedland has been involved in HIV/AIDS international
educational programs as a member of the Governing Council of the International AIDS Society and is currently actively
involved in issues of antiretroviral therapy access, training and provision in South Africa. He is a Visiting Professor
at the Nelson Mandela School of Medicine in Durban, South Africa.
|
